Literature DB >> 27070699

Intratumoral Heterogeneity of the Epigenome.

Tali Mazor1, Aleksandr Pankov1,2, Jun S Song2,3,4,5, Joseph F Costello1.   

Abstract

Investigation into intratumoral heterogeneity (ITH) of the epigenome is in a formative stage. The patterns of tumor evolution inferred from epigenetic ITH and genetic ITH are remarkably similar, suggesting widespread co-dependency of these disparate mechanisms. The biological and clinical relevance of epigenetic ITH are becoming more apparent. Rare tumor cells with unique and reversible epigenetic states may drive drug resistance, and the degree of epigenetic ITH at diagnosis may predict patient outcome. This perspective presents these current concepts and clinical implications of epigenetic ITH, and the experimental and computational techniques at the forefront of ITH exploration.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27070699      PMCID: PMC4852161          DOI: 10.1016/j.ccell.2016.03.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  131 in total

1.  Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.

Authors:  J R Graff; E Gabrielson; H Fujii; S B Baylin; J G Herman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

2.  Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.

Authors:  T Watanabe; M Nakamura; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

Review 3.  Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance.

Authors:  S Cara; I F Tannock
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

4.  p14ARF deletion and methylation in genetic pathways to glioblastomas.

Authors:  M Nakamura; T Watanabe; U Klangby; C Asker; K Wiman; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  2001-04       Impact factor: 6.508

5.  MethyLight: a high-throughput assay to measure DNA methylation.

Authors:  C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

6.  Promoter hypermethylation of the RB1 gene in glioblastomas.

Authors:  M Nakamura; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Lab Invest       Date:  2001-01       Impact factor: 5.662

7.  Induction of tumors in mice by genomic hypomethylation.

Authors:  François Gaudet; J Graeme Hodgson; Amir Eden; Laurie Jackson-Grusby; Jessica Dausman; Joe W Gray; Heinrich Leonhardt; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

8.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.

Authors:  C A Eads; R V Lord; S K Kurumboor; K Wickramasinghe; M L Skinner; T I Long; J H Peters; T R DeMeester; K D Danenberg; P V Danenberg; P W Laird; K A Skinner
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

10.  Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Brian J Reid
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  79 in total

1.  CORR® Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

Review 2.  Defining, distinguishing and detecting the contribution of heterogeneous methylation to cancer heterogeneity.

Authors:  Thomas R Pisanic; Pornpat Athamanolap; Tza-Huei Wang
Journal:  Semin Cell Dev Biol       Date:  2016-08-28       Impact factor: 7.727

3.  Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.

Authors:  Chin-Hsing Annie Lin; Christopher T Rhodes; ChenWei Lin; Joanna J Phillips; Mitchel S Berger
Journal:  Cell Cycle       Date:  2017-02-22       Impact factor: 4.534

4.  Quantitative comparison of within-sample heterogeneity scores for DNA methylation data.

Authors:  Michael Scherer; Almut Nebel; Andre Franke; Jörn Walter; Thomas Lengauer; Christoph Bock; Fabian Müller; Markus List
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

Review 5.  A population genetics perspective on the determinants of intra-tumor heterogeneity.

Authors:  Zheng Hu; Ruping Sun; Christina Curtis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-06       Impact factor: 10.680

Review 6.  Unravelling biology and shifting paradigms in cancer with single-cell sequencing.

Authors:  Timour Baslan; James Hicks
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 7.  Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics.

Authors:  Himadri Patel; Pritish Nilendu; Devashree Jahagirdar; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

Review 8.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

Review 9.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

10.  Paradoxical association of TET loss of function with genome-wide DNA hypomethylation.

Authors:  Isaac F López-Moyado; Ageliki Tsagaratou; Hiroshi Yuita; Hyungseok Seo; Benjamin Delatte; Sven Heinz; Christopher Benner; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.